Other meanings of CYP3A4
PHARMACOLOGY
CYP3A4 is a human cytochrome P450 enzyme that oxidizes and clears many medicines, environmental chemicals, and endogenous compounds. It is especially abundant in the liver and small intestine, making its activity a major determinant of oral drug exposure and a frequent source of drug–drug interactions.1
CYP3A4 catalyzes oxidative metabolism of a broad and chemically diverse set of substrates. As a heme-containing member of the cytochrome P450 family, it uses molecular oxygen and reducing equivalents to introduce or expose functional groups, often producing metabolites that are more readily eliminated.2 The enzyme is expressed mainly in the liver and along the intestinal epithelium, where it can reduce the fraction of an orally administered dose reaching the bloodstream. This intestinal first-pass metabolism is one reason the same medicine may have substantially different oral and intravenous pharmacokinetics. CYP3A4 also contributes to the metabolism of endogenous steroids, bile acids, and other lipophilic molecules, although its clinical importance is most visible in pharmacology. The related enzyme CYP3A5 overlaps with some substrates but has distinct expression patterns.1
CYP3A4 activity can be changed rapidly by inhibitors and more gradually by enzyme inducers, altering concentrations of co-administered medicines. Strong inhibitors such as clarithromycin, itraconazole, and ritonavir can increase exposure to sensitive substrates, sometimes causing serious toxicity; the magnitude depends on dose, route, timing, and the patient’s other clearance pathways. Rifampicin and certain anticonvulsants induce CYP3A4 through transcriptional mechanisms, often lowering substrate concentrations and reducing therapeutic effect. Grapefruit juice is a distinctive edge case: constituents can inhibit intestinal CYP3A4 without equivalently inhibiting hepatic enzyme, so the interaction is strongest for susceptible oral drugs and varies with product and amount. Interaction warnings therefore apply to particular drug pairs, not automatically to every CYP3A4 substrate.
CYP3A4-mediated clearance varies substantially between individuals, but routine genetic prediction is less straightforward than for several other drug-metabolizing enzymes. The CYP3A4 gene generally has fewer common, strongly functional variants than CYP2D6, while differences in liver disease, age, inflammation, diet, concomitant medicines, and tissue expression can be clinically important.1 A medicine’s vulnerability depends not only on whether CYP3A4 metabolizes it, but also on its therapeutic window, active metabolites, intestinal extraction, transporters, and alternative enzymes. Midazolam is widely used as a sensitive probe substrate in pharmacokinetic studies, whereas tacrolimus exposure is influenced importantly by both CYP3A4 and CYP3A5. Clinical management usually emphasizes medication review, avoidance of high-risk combinations, dose adjustment, and therapeutic-drug monitoring where validated rather than a CYP3A4 genotype alone.3
CYP3A4 is not simply a uniform liver enzyme: its abundance and activity differ between tissues, and intestinal expression can create a presystemic metabolic barrier before a drug enters circulation. Enzyme activity may also be changed by inflammation and other physiological states, complicating predictions based solely on healthy-volunteer studies.2 Some interactions are mechanism-based: a compound is metabolized to a reactive species that irreversibly reduces enzyme activity, so inhibition can persist after the compound has left the blood. Conversely, induction usually requires new protein synthesis and may take days to develop and to resolve. CYP3A4 substrates can also compete for metabolism, although clinically meaningful competition is often less predictable than inhibition. These distinctions explain why product labeling and regulatory interaction studies separate reversible inhibition, mechanism-based inhibition, and induction rather than treating them as one phenomenon.
CYP3A4 effects are medicine-specific; the presence of CYP3A4 metabolism alone does not establish that a clinically important interaction will occur.
Help improve the encyclopedia. Reports go straight to the site manager.